To understand why once-weekly isoniazid/rifapentine therapy for than rifampin (14-15 hours versus 2-5 hours, respectively) tuberculosis was less effective than twice-weekly isoniazid/rifampin, was undertaken with the hope that it would allow highly we studied human immunodeficiency virus-seronegative patients active once-weekly therapy. However, in three large randomwith either failure (n ϭ 4), relapse (n ϭ 35), or cure (n ϭ 94), reized trials (1-3), once-weekly isoniazid/rifapentine was less cruited from a comparative treatment trial. In multivariate analyses effective than twice-or thrice-weekly isoniazid/rifampin in that were adjusted for severity of disease, low plasma concentrathe last 4 months of treatment of active tuberculosis.
tions to improve the activity of once-weekly therapy: increaskinetics ing the dose of rifapentine by the former suggestion versus improving the activity of the companion drug in the latter. Directly observed therapy is one of the key elements of To evaluate the reasons for decreased activity of once-weekly efforts to improve tuberculosis control around the world.
isoniazid/rifapentine, we evaluated pharmacokinetic parameIntermittent dosing facilitates directly observed therapy by ters of isoniazid, rifapentine, and rifampin among patients decreasing the number of required encounters between paenrolled in the Tuberculosis Trials Consortium (TBTC)/ tient and the treatment provider. The development of rifaUnited States Public Health Service randomized trial involvpentine, a rifamycin antibiotic with a much longer half-life ing this regimen (3) . Some of the results of the pharmacokinetic substudy have been previously reported in the form of abstracts (6, 7) .
(Received in original form August 27, 2002; accepted in final form January 14, 2003) dose of the regimen received during the study. In the prospective phase, ure/relapse in proportional hazards analysis of the parent trial (positive 50 HIV-seronegative patients were enrolled while still on study treatsputum culture at 2 months of treatment, cavitation on chest radiograph, ment (outcomes later determined for these patients). In addition, 33 greater than or equal to 10% under ideal body weight, bilateral disease HIV-seropositive patients were enrolled. The pharmacokinetic subon chest radiograph, and non-Hispanic white race). study was approved by the Institutional Review Boards of the CDC and of 26 participating TBTC sites.
METHODS

COMPARISON OF THE DEMOGRAPHIC, CLINICAL, AND RADIOGRAPHIC CHARACTERISTICS OF HUMAN IMMUNODEFICIENCY VIRUS-SERONEGATIVE CONTROL CASES AND TREATMENT FAILURE/RELAPSE CASES IN THE PHARMACOKINETIC SUBSTUDY WITH THE OTHER HUMAN IMMUNODEFICIENCY VIRUS-SERONEGATIVE CASES IN THE PARENT STUDY (TUBERCULOSIS TRIALS CONSORTIUM STUDY 22)
RESULTS
Sample Collection, Drug, and Genotype Analyses Subjects Blood samples for analyses were collected just before an observed dose
The demographics and clinical characteristics of the 133 HIVand then 1, 2, 5, and 24 hours afterward (and 48 hours for rifapentine).
seronegative patients in the pharmacokinetic substudy were simPatients received medications under the same conditions (fasting or fed) that they received their TBTC Study 22 therapy. Standard techniques ilar to those of all HIV-seronegative patients in Study 22 (Tawere used for sample preparation (8) , HPLC analyses of plasma drug ble 1). In the retrospective phase, 4 patients with failure, 33 concentrations (MDS Pharma Services, Montreal, QC), and N-acetylpatients with relapse, and 46 control patients with cure were transferase genotyping (9) . enrolled. In the prospective phase 50 patients were enrolled, of whom one had failure, two had relapse, and 47 were cured.
Statistical and Pharmacokinetic Analyses
Combining the retrospective and prospective phases of the study, All primary analyses were performed in 133 HIV-seronegative patients. 54% of the patients (40 of 74) who failed or relapsed in the The primary null hypothesis was that there were no differences in parent trial underwent pharmacokinetic sampling.
isoniazid or rifamycin pharmacokinetic parameters in HIV-seronegative patients with the endpoints of cure versus failure/relapse.
After establishing the similarity of pharmacokinetic parameters Comparison of Pharmacokinetic Parameters among retrospectively and prospectively sampled patients, we combined among Retrospectively Sampled versus these two groups, and for the remainder of the analyses compared all Prospectively Sampled Patients patients with failure/relapse with those who had been cured. We adTo determine if time of sampling affected isoniazid or rifamycin justed for rifampin autoinduction. In patients who had not received a dose of rifampin within 14 days before sampling, the estimated rifampin pharmacokinetics, pharmacokinetic parameters were compared area under the concentration-time curve (AUC 0-12 ) was decreased by 24%, among control cases sampled retrospectively to study therapy the serum half-life by 44%, and the maximal concentration (Cmax) by 4% versus control cases sampled prospectively ( Table 2 ). The control (10). Isoniazid and rifapentine (11-13) parameters were not adjusted.
cases were compared in this analysis because only three patients Analyses of pharmacokinetic parameters were performed using nonwith failure or relapse were sampled prospectively. On initial compartmental techniques (14, 15) . Because a sparse sampling method analysis, all rifampin pharmacokinetic parameters were lower was used, pharmacokinetic parameters (half-life and AUC 0-12 ) approximate what would have been obtained with more frequent sampling.
in prospectively sampled patients compared with retrospectively Data analyses were performed using SAS software (Cary, NC). Difsampled patients. However, after adjustment for rifampin auferences between groups were determined using the 2 statistic. The toinduction, these differences narrowed. The only significant
Mann-Whitney U test was used for non-normally distributed data. among patients with failure or relapse compared with control
COMPARISON OF PHARMACOKINETIC PARAMETERS OF ISONIAZID, RIFAMPIN, AND RIFAPENTINE FROM THE CASES WHO WERE CURED AND EITHER SAMPLED RETROSPECTIVELY (AFTER COMPLETING STUDY THERAPY) OR SAMPLED PROSPECTIVELY (DURING STUDY TREATMENT)
Association of Pharmacokinetic Parameters with
cases. However, there was no association between the Cmax or
Treatment Outcome
AUC of either rifamycin and treatment outcome. If these analyAmong patients treated with once-weekly isoniazid/rifapentine, ses were repeated in only patients sampled retrospectively, the all isoniazid pharmacokinetic parameters (area under the consame associations between isoniazid and rifamycin pharmacokicentration-time curve during 12 hours after dosing [AUC 0-12 ], netic parameters versus treatment outcome were found (data maximal concentration [Cmax] and half-life) were lower among not shown). Finally, these results were similar when restricted patients with failure or relapse compared with control cases to patients with relapse and cure (i.e., patients with failure ex-( Table 3 ). For example, the median isoniazid AUC 0-12 in 22
cluded; data not shown). patients with failure/relapse was 36.0 versus 55.9 g · hour/ml
In proportional hazards regression analyses, we adjusted for in 49 patients with cure (p ϭ 0.005, Mann-Whitney U test and demographic and clinical factors associated with treatment out- Figure E1A in the online supplement). In contrast in 49 patients come in the parent trial (a positive sputum culture at 2 months treated with twice-weekly therapy, isoniazid levels did not sigof treatment, cavitation on chest radiograph, being underweight, nificantly differ between failure/relapse and cure (isoniazid having bilateral disease on chest radiograph, or being of non-AUC 0-12 p ϭ 0.65, Table 3 and Figure E1A in the online suppleHispanic white race). In these analyses, isoniazid pharmacokiment). Of note, isoniazid AUC 0-12 was not significantly different netic parameters retained their association with failure or rebetween all cases in the once-weekly treatment arm versus the lapse, whereas no rifamycin pharmacokinetic parameter was astwice-weekly treatment arm (p ϭ 0.25).
Rifamycin half-lives by univariate analyses were shorter sociated with treatment outcome (Table 4) . To illustrate the Definition of abbreviations: AUC 0-12 ϭ area under the concentration-time curve during 12 hours after dosing; CI ϭ confidence interval.
In the multivariate proportional hazards models, covariates with a probability Ͻ 0.15 were entered in a stepwise procedure with the isoniazid AUC 0-12 (continuous variable), rifampin AUC 0-12 adjusted for autoinduction (continuous variable) or rifapentine half-life (continuous variable), sputum culture after 2-months treatment for Mycobacterium tuberculosis (positive or negative), underweight at 2 months (yes or no), radiographic lung cavities at baseline or 2-months treatment (present or none), white nonHispanic race (yes or no) and bilateral lung disease (yes or no). Hazard ratios expressed for the continuous AUC 0-12 parameter for a decrease 1 g · hour/ml, and half-life for a decrease of 1 hour.
magnitude of the effect of isoniazid pharmacokinetic parameters associated with outcome in cases treated with once-weekly isoniazid/rifapentine compared with all control cases with cure (p ϭ relative to the previously identified demographic and clinical risk factors for failure or relapse, we dichotomized isoniazid 0.03, 2 ). By contrast, phenotype in cases treated with twice per week isoniazid/rifampin was not significantly associated with pharmacokinetic parameters at the median value and repeated the multivariate analyses (data not shown). When analyzed in outcome (p ϭ 0.18). Of note, there was a highly significant association between NAT2 phenotype and isoniazid AUC 0-12 this manner, low isoniazid AUC 0-12 among HIV-seronegative patients treated with the once-weekly regimen was associated (p Ͻ 0.0001). with failure or relapse with a hazard ratio (5.99) similar to clinical
Relapse of M. tuberculosis Monoresistant to Rifamycin in risk factors such as cavitation on chest radiograph or having a
Two Patients with Low Isoniazid Concentrations
positive sputum culture at 2 months of therapy (Table 4) .
Five patients relapsed with M. tuberculosis monoresistant to
N-acetyl-transferase Type 2 Genotype and
rifamycin in the TBTC Study 22 (3, 4) . Four of these patients
Treatment Outcome
were coinfected with HIV and were treated with once-weekly isoniazid/rifapentine; the fifth patient was HIV-seronegative and Isoniazid acetylator status was determined by N-acetyl-transferase type 2 (NAT2) genotype in 89 HIV-seronegative cases was treated with twice-weekly rifampin. Two of the five cases in TBTC Study 22 with acquired rifamycin-resistant relapse had (Table 5 ). NAT2 phenotype, as determined by genotype, was remained the same. In 18 HIV-seropositive cases treated with once-per-week therapy, the median isoniazid AUC 0-12 was lower in 2 patients who relapsed versus 16 control cases (AUC 0-12 23.8 vs. 60.6 g · hour/ml, p ϭ 0.16, Mann-Whitney). By comparison, in the 15 HIV-seropositive patients treated twice per week with isoniazid and rifampin, the median isoniazid AUC 0-12 was similar in two cases with relapse versus the 13 control cases (41.9 versus 48.7 g · hour/ml, p ϭ 0.87). Furthermore, the association of pharmacokinetic parameters with treatment outcome remained the same if all HIV-seropositive and HIV-seronegative cases were analyzed together (n ϭ 152 with isoniazid AUC 0-12 determined). Specifically, median isoniazid AUC 0-12 in 88 cases receiving onceweekly isoniazid and rifapentine was lower in 24 patients with failure or relapse versus 64 cures (AUC 0-12 34.9 versus 56.2 g · hour/ml, p ϭ 0.002). As before, the median isoniazid AUC 0-12 in the 64 cases receiving twice-weekly isoniazid and rifampin were similar in 18 patients with failure or relapse and the 46 cures (AUC 0-12 43.3 versus 48.7 g · hour/ml, p ϭ 0.7).
N-ACETYL-TRANSFERASE TYPE 2 PHENOTYPE (DETERMINED BY GENOTYPE) AND TREATMENT OUTCOME IN HUMAN IMMUNODEFICIENCY VIRUS-SERONEGATIVE PATIENTS WITH FAILURE/RELAPSE COMPARED WITH ALL CONTROL CASES WITH CURE
DISCUSSION
Three independent lines of evidence in this study suggest that isoniazid pharmacokinetics explain at least part of the decrease in efficacy of the once-weekly isoniazid/rifapentine regimen. First, there was a strong relationship between several isoniazid pharmacokinetic parameters and the occurrence of failure or relapse among patients treated with once-weekly therapy. This association remained strong after adjustment for demographic and clinical risk factors for failure or relapse. Second, an independently analyzed marker of isoniazid pharmacokinetics, the presence of NAT2 genotypes that more rapidly metabolize isoniazid, with once-weekly therapy. Finally, the finding that all cases of (A ) Mean isoniazid concentrations (Ϯ SE g/ml) are depicted 1, 2, and acquired resistance had acquired rifamycin-monoresistance is the number of patients was low, baseline isoniazid resistance was not a risk factor for failure or relapse among patients in the Hong Kong trial (1, 16, 17) of once-weekly isoniazid/rifapentine pharmacokinetic sampling performed ( Figure 1A ) in the subs-(2/16 [12.5%] having isoniazid-resistant isolates relapsed versus tudy; both had very low concentrations of isoniazid at all time 38/346 [11.0%] of those with isoniazid-susceptible isolates). Furpoints and low pharmacokinetic parameters. Of note, rifamycin thermore, in the Hong Kong trial, rapid acetylators of isoniazid concentrations were obtained from the HIV-negative patient, (determined by NAT2 genotyping) were not at higher risk of and in this case rifampin concentrations were comparable with failure or relapse. those obtained from all other patients ( Figure 1B) .
Despite the impressive evidence suggesting that isoniazid
Association of Pharmacokinetic Parameters with
plays a minor role in standard twice-weekly rifampin-based ther-
Treatment Outcome in HIV-Seropositive Patients
apy, evidence from several sources suggests that this conclusion may not be true for once-weekly therapy. In the British Medical Of the 33 HIV-seropositive patients in the pharmacokinetic Research Council Singapore trial of once-weekly regimens of study, 4 relapsed and 29 were cured. The median CD4 cell count isoniazid and rifampin (18) , rapid acetylators of isoniazid were at the time of the pharmacokinetic study was 240 cells/mm 3 at greater risk of failure (12/155 rapid acetylators [8%], but 0/ (interquartile range 166-383), the median viral load was 11,244 117 slow acetylators) but not of relapse. Furthermore, in a mouse copies/mm 3 (interquartile range 593-69,083). model of tuberculosis treatment that has correlated closely with Because prior studies of tuberculosis treatment outcomes and the results of human clinical trials, once-weekly therapy with pharmacokinetic parameters were evaluated in HIV-seronegaisoniazid/rifapentine was associated with a low risk of acquired tive patients and because the number of HIV-seropositive parifamycin-monoresistance (19). In further experiments (20) intients in this pharmacokinetic substudy was small, all primary volving once-weekly rifapentine-based regimens, the occurrence analyses were done in the HIV-seronegative population. In secondary analyses with the 33 HIV-seropositive cases, the findings of acquired rifamycin-monoresistance was prevented by supple-menting the regimen with daily isoniazid or weekly moxifloxacin parameters of patients sampled prospectively were quite similar to those of patients sampled retrospectively in this study. Thus, but not by increasing the dose of rifapentine.
Despite similar overall rates of failure/relapse in the two it was unlikely that our use of retrospective sampling resulted in a systematic bias in this analysis. Our sampling scheme (five treatment arms, there were significant differences between the Hong Kong trial and TBTC Study 22 cohorts in risk factors for time points per patient) was not sufficient to determine some pharmacokinetic parameters, like half-life, with a high degree failure/relapse. Two-month culture positivity was detected in only 8.2% of 522 cases from Hong Kong (1, 16, 17) versus 20% of accuracy. However, the robustness of the findings suggests that this sampling scheme was sufficient to detect relevant differof 886 in TBTC 22 (p Ͻ 0.0001). Radiographic lung cavitation was identified in 37% of 592 cases from Hong Kong versus 54% ences in pharmacokinetic parameters. Residual confounding by measured or unmeasured variables is possible, but the risk facof 975 in TBTC 22 (p Ͻ 0.0001). These two differences suggest that patients enrolled in TBTC 22 may have had more advanced tors for failure or relapse identified in the 1,004 patients in TBTC Study 22 were used to adjust relative risk in multivariate analyses. disease than the population in the Hong Kong trial. This difference in disease severity may, in part, account for the different Finally, our study did not use all possible restriction enzymes to detect slow acetylator genotypes. Unfortunately, the NAT2 conclusions about the role of isoniazid.
Finally, it is notable that the isoniazid pharmacokinetic pagenetic analysis was incomplete; two mutations-G191A and rameter having the strongest association with treatment failure A341C with frequencies in African Americans of 9 and 6%, or relapse was AUC, not Cmax (Table 3 ). This finding is consisrespectively (9)-could not be detected. In the study, 4 of 22 tent with the results in early studies of once-weekly isoniazid African Americans were discordant between phenotype deterplus streptomycin, in which increasing the isoniazid dose among mined by drug pharmacokinetic sampling and by NAT2 genorapid acetylators (which increased the Cmax, but had much less type. However, detection of these mutations in the four discoreffect on AUC) did not alter their increased risk of treatment dant cases would have changed the genotype designations so as failure (21, 22) . Both results suggest that time over a critical to further support the association of NAT2 genotypes with failconcentration (as approximated by AUC) is a more important ure/relapse with once-weekly isoniazid/rifapentine but not twicedeterminant of the success of highly intermittent isoniazid therweekly isoniazid/rifampin. apy than is peak drug concentration (Cmax).
In summary, our study offers strong evidence that isoniazid An important negative finding in this study was the lack of plays a significant role in once-weekly rifapentine/isoniazid therconsistent association between pharmacokinetic parameters and apy. Increasing the dose of rifapentine (27) may also increase the occurrence of failure or relapse in HIV-seronegative patients the potency of once-weekly therapy, as was suggested by the given twice-weekly isoniazid and rifampin. Prior uncontrolled mouse model, but is unlikely to result in highly active therapy studies (23, 24) have reported low serum concentrations of rifamthat completely prevents acquired rifamycin-resistance. The impin among patients who had failure or relapse with standard plication of this finding is that efforts to strengthen once-weekly rifampin-based regimens. These studies have been interpreted therapy should include some alteration to the nonrifamycin poras demonstrating that abnormal pharmacokinetics were an imtion of the regimen. Interventions that may be effective include portant cause of poor outcome with standard therapy. However, adding a drug with a longer half-life, such as moxifloxacin, or these studies had major methodological problems. The most supplementing the regimen with daily isoniazid. Finally, these serious problem was the lack of pharmacokinetic data from a results illustrate the usefulness of incorporating pharmacokinetic control population of patients who were cured. In addition, these measurements into studies evaluating new treatment regimens. studies assessed only one or two time points and thus may have substantially underestimated the peak serum concentration, the (11-13, 26 ). In addition, after adjustment for the welldescribed effects of rifampin autoinduction, pharmacokinetic Margaret Lankford, R.N., Charlotte Quinlan-Mauzy, R.N. [7] ),
